Areplivir
| LP-006288 | |
| Name | Areplivir |
| Dosage form | Tablets |
| Nosological classification | J05AX27 |
| INN | Favipiravir |
| Active agent | Active ingredient: Favipiravir — 200.0 mg Excipients: Povidone (K-30), colloidal silicon dioxide, low substituted hydroxypropyl cellulose, microcrystalline cellulose (type 101), crospovidone, stearic acid. Film coating: Pre-finished film coating Opadray® 03F220114 yellow [hypromellose, titanium dioxide, macrogol 4000 (polyethylene glycol 4000), yellow ferric oxide E172]. |
Areplivir blocks the reproduction of RNA viruses and triggers the processes of self-destruction of viral particles:
as early as on the 1st day of treatment, a turning-point in the disease is observed in 80% of patients;
on the 3rd day, fever disappears, symptoms of intoxication decrease, and general condition improves;
on the 5th day, virus elimination and a clear decrease in signs of inflammation is achieved in 78% of patients.
Areplivir (lyophilizate) is used intravenously in hospitals, Areplivir (tablets) – in outpatient practice and in hospitals. Areplivir has a large evidence base and wide experience of use; its efficacy and safety are well studied and repeatedly confirmed by use in real clinical practice.
The drug is prescribed depending on body weight.
The administration of Areplivir can be started any day from the disease onset and up to 10 days or until the complete elimination of the virus following the doctor’s advice.
- L. A. Balykova et al. / Infectious diseases, 2020, volume 18, No. 3, in press Report on the results of the clinical study "Open-label randomized multicenter comparative study of the efficacy and safety of Areplivir film-coated tablets (PROMOMED RUS LLC, Russia) in patients hospitalized with COVID-19"
- Prescription product. Consult a doctor before use.
